MONOPRIL-HCT
LOE ApproachingNDAORALTABLET
Approved
Nov 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MONOPRIL-HCT is a fixed-dose combination oral tablet approved in 1994 combining an ACE inhibitor with a thiazide diuretic. The product treats hypertension by reducing blood pressure through dual mechanism: ACE inhibition and diuretic action. It is indicated for patients requiring combination antihypertensive therapy.
LOE Approaching
Product approaching loss of exclusivity in a mature, competitive hypertension market; expect declining commercial team investment and focus on generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's mature, LOE-approaching status with declining commercial investment. Career opportunities on this product are limited and increasingly focused on generic transition and lifecycle management rather than growth activities.
Brand ManagerField Sales Representative
Worked on MONOPRIL-HCT at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.